Pfizer secures rights for RSV therapeutic candidate sisunatovir in China
Pharmaceutical Technology
DECEMBER 20, 2022
Under the deal terms, LianBio will receive an upfront payment of $20m and is also eligible for up to $135m in potential development and commercial milestones and net sales of sisunatovir in the territories. In 2020, LianBio and Pfizer partnered to develop and commercialise transformative pharmaceutical products in Greater China.
Let's personalize your content